| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Sodium channels on nerve cell membranes. Butacaine is a reversible nerve conduction blocker that acts by binding to voltage-gated sodium channels on nerve cell membranes, preventing sodium ion influx and thereby blocking action potential generation and propagation. This results in reversible loss of sensation in the area of application. As a PABA ester-type local anesthetic, its mechanism is similar to that of procaine and other related compounds.
|
|---|---|
| ln Vitro |
In vitro, Butacaine exhibits local anesthetic activity by blocking nerve conduction in isolated nerve preparations. The compound's potency and duration of action can be assessed in vitro using isolated frog sciatic nerve or rat phrenic nerve preparations. Nerve conduction blockade is measured by stimulating the nerve and recording compound action potentials before and after drug application. Butacaine's local anesthetic activity is concentration-dependent and reversible upon washout.
|
| ln Vivo |
In vivo, Butacaine is used as a local anesthetic for topical and infiltrative anesthesia. Its in vivo effects have been characterized in animal models and in clinical applications. The compound produces reversible blockade of sensory and motor nerve function in the area of application. Its onset of action and duration of anesthesia have been evaluated in various animal models including the guinea pig wheal test and the rabbit corneal reflex test.
|
| Enzyme Assay |
In vitro sodium channel binding assays for Butacaine measure its affinity for voltage-gated sodium channels. The assay uses membrane preparations from brain or other neural tissues and radiolabeled sodium channel ligands such as [3H]-batrachotoxin or [3H]-saxitoxin. Varying concentrations of Butacaine are incubated with membranes and radioligand. Non-specific binding is determined in the presence of excess unlabeled ligand. After incubation, bound and free radioligands are separated by filtration, and radioactivity is counted. IC50 and Ki values are calculated from competition curves using nonlinear regression analysis.
|
| Cell Assay |
In vitro cell-based assays for Butacaine use neuronal cell lines or primary neuronal cultures. Cells are loaded with voltage-sensitive fluorescent dyes (e.g., Di-8-ANEPPS) or patch-clamp electrophysiology is used to measure sodium currents. Cells are treated with varying concentrations of Butacaine, and sodium channel blockade is measured as a reduction in sodium current amplitude or fluorescence signal. IC50 values are calculated from dose-response curves. The reversibility of the blockade can be assessed by washout experiments.
|
| Animal Protocol |
In vivo animal studies for Butacaine are conducted in various animal models of local anesthesia. The guinea pig wheal test involves intradermal injection of the compound and assessment of the area of anesthesia. The rabbit corneal reflex test measures the loss of blink reflex following topical application to the cornea. The sciatic nerve block model in rats involves injection of the compound around the sciatic nerve and assessment of motor and sensory function blockade. Duration of action, potency, and toxicity are evaluated in these models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Butacaine are characteristic of ester-type local anesthetics. With a molecular weight of 306.44 and a pKa of 8.96, the compound exists predominantly in the ionized form at physiological pH, which limits its ability to cross lipid membranes. It is metabolized by plasma esterases (pseudocholinesterase) to para-aminobenzoic acid (PABA) and dibutylaminoethanol. The compound has a relatively short duration of action due to rapid hydrolysis. It is typically administered topically or by local injection.
|
| Toxicity/Toxicokinetics |
Toxicological data for Butacaine indicate that it is classified as highly toxic with a subcutaneous LDL0 of 150 mg/kg in rats and 100 mg/kg in mice. As a local anesthetic, it shares the potential for systemic toxicity with other agents in this class, including central nervous system excitation followed by depression, and cardiovascular effects including hypotension and cardiac arrhythmias. Allergic reactions may occur due to the PABA structure. The compound is a combustible solid. Butacaine is used clinically as a local anesthetic.
|
| Additional Infomation |
3-(dibutylamino)propyl 4-aminobenzoic acid is a benzoic acid ester.
Butacaine is a clinically used ester-type local anesthetic for topical and infiltrative anesthesia. Its chemical name is 1-Propanol, 3-(dibutylamino)-, 4-aminobenzoate (ester). The compound has a molecular formula of C18H30N2O2 and molecular weight of 306.44. It is a reversible nerve conduction blocker that acts on voltage-gated sodium channels. Butacaine is classified as a PABA ester local anesthetic. It is available as a research and clinical reagent. Approved for clinical use as a local anesthetic. |
| Molecular Formula |
C18H30N2O2
|
|---|---|
| Molecular Weight |
306.443
|
| Exact Mass |
306.231
|
| CAS # |
149-16-6
|
| PubChem CID |
2480
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.014g/cm3
|
| Boiling Point |
440ºC at 760 mmHg
|
| Melting Point |
25°C
|
| Flash Point |
219.9ºC
|
| Vapour Pressure |
6.1E-08mmHg at 25°C
|
| Index of Refraction |
1.523
|
| LogP |
4.299
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
22
|
| Complexity |
281
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCN(CCCOC(C1=CC=C(N)C=C1)=O)CCCC
|
| InChi Key |
HQFWVSGBVLEQGA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H30N2O2/c1-3-5-12-20(13-6-4-2)14-7-15-22-18(21)16-8-10-17(19)11-9-16/h8-11H,3-7,12-15,19H2,1-2H3
|
| Chemical Name |
3-(dibutylamino)propyl 4-aminobenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~326.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.79 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2633 mL | 16.3164 mL | 32.6328 mL | |
| 5 mM | 0.6527 mL | 3.2633 mL | 6.5266 mL | |
| 10 mM | 0.3263 mL | 1.6316 mL | 3.2633 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
